We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
-1.91%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$151M
AUM Growth
+$10.1M
Cap. Flow
+$16.3M
Cap. Flow %
10.8%
Top 10 Hldgs %
48.77%
Holding
155
New
39
Increased
47
Reduced
18
Closed
28

Top Buys

Rank Stock Value
1
CPNG icon
Coupang
CPNG
+$8.86M
2
KSU
Kansas City Southern
KSU
+$3.59M
3
CHNG
Change Healthcare Inc. Common Stock
CHNG
+$3.54M
4
PPD
PPD, Inc. Common Stock
PPD
+$3.47M
5
FIVN icon
FIVE9
FIVN
+$3.18M

Top Sells

Rank Stock Value
1
WTW icon
Willis Towers Watson
WTW
+$9.44M
2
MXIM
Maxim Integrated Products
MXIM
+$4.49M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$3.96M
4
WORK
Slack Technologies, Inc.
WORK
+$3.57M
5
SOGO
Sogou Inc. American Depositary Shares, each representing one Class A Ordinary Share
SOGO
+$3.07M

Sector Composition

Rank Sector Weight
1 Healthcare 44.08%
2 Technology 31.3%
3 Consumer Discretionary 7.05%
4 Communication Services 3.66%
5 Industrials 2.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRIS icon
26
Curis
CRIS
$7.13M
$1.35M 0.89%
431
+286
+197% +$893K
KURA icon
27
Kura Oncology
KURA
$874M
$1.33M 0.88%
70,888
+32,460
+84% +$612K
CCCC icon
28
C4 Therapeutics
CCCC
$400M
$1.31M 0.87%
29,341
+7,612
+35% +$326K
BPMC
29
DELISTED
Blueprint Medicines
BPMC
$1.31M 0.86%
12,716
+3,911
+44% +$364K
TIL icon
30
Instil Bio
TIL
$50.3M
$1.29M 0.85%
3,604
+1,532
+74% +$572K
NVTA
31
DELISTED
Invitae Corporation
NVTA
$1.28M 0.85%
44,967
+18,097
+67% +$530K
NBIX icon
32
Neurocrine Biosciences
NBIX
$16.8B
$1.27M 0.84%
13,205
+5,065
+62% +$478K
HZNP
33
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.24M 0.82%
11,298
+2,619
+30% +$272K
NTRA icon
34
Natera
NTRA
$45.9B
$1.23M 0.81%
+11,039
New +$1.27M
RCKT icon
35
Rocket Pharmaceuticals
RCKT
$397M
$1.22M 0.8%
40,671
+22,247
+121% +$810K
STOK icon
36
Stoke Therapeutics
STOK
$2.08B
$1.21M 0.8%
+47,594
New +$1.33M
VTGN icon
37
VistaGen Therapeutics
VTGN
$11.7M
$1.2M 0.79%
14,608
+4,338
+42% +$377K
RLAY icon
38
Relay Therapeutics
RLAY
$4.37B
$1.19M 0.79%
37,743
+14,493
+62% +$488K
PMVP icon
39
PMV Pharmaceuticals
PMVP
$65.6M
$1.19M 0.78%
39,777
+16,019
+67% +$511K
ALNY icon
40
Alnylam Pharmaceuticals
ALNY
$29B
$1.16M 0.77%
+6,158
New +$1.16M
BBIO icon
41
BridgeBio Pharma
BBIO
$16.6B
$1.16M 0.76%
24,652
+11,596
+89% +$622K
MORF
42
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.15M 0.76%
20,345
+2,428
+14% +$147K
EPIX
43
DELISTED
ESSA Pharma
EPIX
$1.15M 0.76%
143,566
+119,540
+498% +$1.9M
XENE icon
44
Xenon Pharmaceuticals
XENE
$6.21B
$1.15M 0.76%
75,046
+34,087
+83% +$592K
MGNX icon
45
MacroGenics
MGNX
$259M
$1.13M 0.75%
54,012
+28,908
+115% +$696K
ARGX icon
46
argenx
ARGX
$54.2B
$1.12M 0.74%
3,707
+788
+27% +$250K
UTHR icon
47
United Therapeutics
UTHR
$22.7B
$1.09M 0.72%
+5,904
New +$1.16M
FOLD
48
DELISTED
Amicus Therapeutics
FOLD
$1.08M 0.72%
113,387
+29,016
+34% +$297K
NVAX icon
49
Novavax
NVAX
$1.3B
$1.03M 0.68%
4,978
-123
-2% -$27.1K
ISEE
50
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.02M 0.68%
63,107
-55,858
-47% -$608K
1
2
3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

HighVista Strategies's Q3 2021 Portfolio in Review

As of Q3 2021, HighVista Strategies held 155 positions worth $151M, up 7.2% from $141M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

HighVista Strategies deployed $16.3M of net new capital in Q3 2021, opening 39 new positions and adding to 47 existing holdings. Its largest new stake was Coupang: 256,264 shares worth $7.14M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 32% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Alibaba, an estimated $1.39M trimmed.

  • HighVista Strategies's largest Q3 2021 buy was Coupang: 256,264 shares worth $7.14M.
  • HighVista Strategies added most to ESSA Pharma in Q3 2021, an estimated $1.9M increase.
  • HighVista Strategies's biggest Q3 2021 reduction was Alibaba, cutting an estimated $1.39M.
  • HighVista Strategies fully exited Willis Towers Watson in Q3 2021, selling an estimated $9.44M.
  • HighVista Strategies's ten largest holdings make up 49% of its $151M portfolio in Q3 2021.
  • HighVista Strategies opened 39 new positions and closed 28 in Q3 2021.
  • HighVista Strategies's portfolio value rose 7.2% quarter-over-quarter to $151M.

Based on HighVista Strategies's 13F filing for Q3 2021, filed 15 Nov 2021.